Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended Decembe...(p the period (59357) (6583) (65940...)

Basic net

(loss)

income per

common share

from

continuing

operations (0.56) (0.10) (0.66) 0.14 0.07 0.21

Diluted net

(loss) income

per common

share from

continuing

operations (0.56) (0.10) (0.66) 0.14 0.07 0.21

December 31, December 31,

2007 2006

---------------------------

a.) Royalty expense adjustments:

Reclassification of royalty expense

from selling, general and administrative - 577

Reclassification of royalty expense to

cost of products sold - (196)

------------- -------------

- 381

------------- -------------

b.) Cost of products sold adjustments:

Overvaluation of inventory in 2006 and

its reversal in 2007 (580) 580

Reclassification of royalty expense to

cost of products sold (note a) - 196

Net impact of fair value change of

inventory on acquisition - 700

------------- -------------

(580) 1,476

------------- -------------

c.) Selling, general and administrative

adjustments:

Stock-based compensation in 2006 an
'/>"/>